MIRA INFORM REPORT

 

 

Report No. :

339540

Report Date :

09.09.2015

           

IDENTIFICATION DETAILS

 

Name :

SUNCRANE MEDICINE LTD.

 

 

Registered Office :

7F., No.206, Sec. 2, Nanjing E. Rd., Jhongshan District, Taipei City 104

 

 

Country :

Taiwan

 

 

Date of Incorporation :

7.11.2007

 

 

Com. Reg. No.:

28822864

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Trading of raw material of medicine.

 

 

No. of Employee :

About 30

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

 

 

Payment Behaviour :

Unknown

 

 

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

Taiwan

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

TAIWAN ECONOMIC OVERVIEW

 

Taiwan has a dynamic capitalist economy with gradually decreasing government guidance of investment and foreign trade. Exports, led by electronics, machinery, and petrochemicals have provided the primary impetus for economic development. This heavy dependence on exports exposes the economy to fluctuations in world demand. Taiwan's diplomatic isolation, low birth rate, and rapidly aging population are other major long-term challenges.

Free trade agreements have proliferated in East Asia over the past several years. Following the landmark Economic Cooperation Framework Agreement (ECFA) signed with China in June 2010, Taiwan in July 2013 signed a free trade deal with New Zealand - Taipei’s first-ever with a country with which it does not maintain diplomatic relations - and, in November, inked a trade pact with Singapore. However, follow-on components of the ECFA, including a signed agreement on trade in services and negotiations on trade in goods and dispute resolution, have stalled. In early 2014, the government bowed to public demand and proposed a new law governing the oversight of cross-Strait agreements, before any additional deals with China are implemented; the legislature has yet to vote on such legislation, leaving the future of ECFA up in the air as President MA enters his final full year in office. MA has portrayed ECFA as Taiwan’s key to greater participation in East Asia’s free trade networks.

Taiwan's total fertility rate of just over one child per woman is among the lowest in the world, raising the prospect of future labor shortages, falling domestic demand, and declining tax revenues. Taiwan's population is aging quickly, with the number of people over 65 expected to account for nearly 20% of the island's total population by 2025.

The island runs a trade surplus, largely because of its surplus with China, and its foreign reserves are the world's fifth largest, behind those of China, Japan, Saudi Arabia, and Switzerland. In 2006 China overtook the US to become Taiwan's second-largest source of imports after Japan. China is also the island's number one destination for foreign direct investment. Taiwan since 2009 has gradually loosened rules governing Chinese investment on the island and has also secured greaterMARKET access for its investors in the mainland. In August 2012, the Taiwan Central Bank signed a memorandum of understanding (MOU) on cross-Strait currency settlement with its Chinese counterpart. The MOU allows for the direct settlement of Chinese RMB and the New Taiwan dollar across the Strait, which has helped Taiwan develop into a local RMB hub.

Closer economic links with the mainland bring greater opportunities for Taiwan’s economy but also pose new challenges as the island becomes more economically dependent on China at a time when political differences remain unresolved. During 2014, the press paid increasing attention to domestic economic issues, while pushing aside the debates over trade liberalization that were a hallmark of MA’s tenure. The media focused on the divide between Taiwan’s “haves” and “have nots,” providing extensive coverage of public frustration with stagnant wages, skyrocketing housing prices, and the difficulty of finding decent entry-level jobs.

 

Source : CIA

 

 

 

Contact Points

 

Company Name:

Suncrane Medicine Ltd.

Supplied Name:

Suncrane Medicine Ltd

Trading Address:

7F., No.206, Sec. 2, Nanjing E. Rd., Jhongshan District, Taipei City 104, Taiwan (R.O.C.)

Supplied Address:

7F, No.206, Sec.2, Nan King E. Rd. Taipei, Taiwan

Telephone Number:

+886-2-2518-1121

Fax Number:

+886-2-2504-1641

Note: The complete address is as above.

 

 

Company Identification Details

 

Registered Name:

Suncrane Medicine Ltd.

Registered Address:

7F., No.206, Sec. 2, Nanjing E. Rd., Jhongshan District, Taipei City 104, Taiwan (R.O.C.)

Date of Foundation:

2007-11-7

Registration Number:

28822864

Registry:

Taipei City Government

Registered Capital:

NTD 1,000,000 (USD 30,600)

(As of 2015.9, 1 NTD = 0.0306 USD)

Legal Representatives:

Yumin Wang

Legal Form:

Private Limited Liability Company

Principal Activities:

Trading of raw material of medicine.

Staff:

About 30 employees

Listed at Stock Exchange:

No

Date of Last Annual Return:

2015-7-14

 

 

History

 

Subject was incorporated on 2007-11-7 with registered number 28822864 as Private Limited Liability Company in Taiwan.

 

 

Corporate Structure

 

Subject did not register any subsidiaries or branches; from other source we could not obtain the relevant information, either.

 

 

Shareholders

 

Major Shareholders

(Unit: NTD)

Name

Subscription Amount

Yumin Wang

1,000,000         

 

 

Management Information

 

Core Management

 

Directors

Name

Yumin Wang

Position

Director

 

Personnel Structure

 

Total Employees

About 30 employees

 

 

Operation Information

 

Offices & Factories

 

 

Headquarters

Add

7F., No.206, Sec. 2, Nanjing E. Rd., Jhongshan District, Taipei City 104, Taiwan (R.O.C.)

 

Production Information

 

Subject is a trader of raw material of medicine without any production activities

 

Purchase Information

 

The registered activities of subject:

Business Code

Details

F107030

Wholesale of cleaning supplies

F107080 

Wholesale of environmental agents

F108021

Wholesale of western medicine

F108031 

Wholesale of medical equipment

F108040 

Wholesale of cosmetics

F113010

Wholesale of machinery

F113030 

Wholesale of precision instruments 

F113050 

Wholesale of computer and transactional equipment

F199990 

Other wholesale industries

F207030 

Retail of cleaning supplies

F207080 

Retail of environmental agents

F208021

Retail of western medicine

F208031 

Retail of medical equipment

F208040 

Retail of cosmetic

F208050 

Retail of B class medicine

F213030 

Retail of computer equipment and transactional

F213040

Retail of precision instruments

F213080 

Retail of mechanical appliances

F299990 

Other retail business

F399990 

Other comprehensive retail

F401010 

International trade

I101090 

Food consultancy Services

IG01010

Biological technology services

ZZ99999 

Besides licensed business, all other business items those are not banned or restricted.

 

Subject’s products are purchased from both home and abroad, such as Mainland China, India and Europe

 

Sales Information

 

Subject is engaged in sale of raw material of medicine.

It is introduced that subject’s major products are  Active Pharmaceutical Ingredients

Subject’s sales regions mainly focus on Taiwan domestic market.

Subject’s major customers are manufacturers of medicine

 

Import and export right:

Import right

Yes

Export right

Yes

 

 

Settlements

 

Purchase

 

Domestic Purchase

Products

Raw material of medicine.

Payment Terms

T/T, Cash

 

Import

Products

Raw material of medicine.

Payment Terms

L/C, T/T

 

Sales

 

Domestic Markets

Product

Raw material of medicine.

Selling Terms

T/T, Cash

 

Export

 

Subject has little export.

 

 

Financial Information

 

Subject has no obligations to disclose its financial statements to the third party according to the relevant policy in Taiwan and the only source from which we can obtain the information is the subject itself.

Subject’s relevant staff declined to disclose its financials citing the grounds of company’s confidentiality; from other sources we could not obtain such information, either.

 

 

Bankers

 

Subject declined to disclose its bank details; from other source we could not obtain the relevant information, either.

 

 

Public Record

 

Mortgage

 

No chattel mortgage record of subject has been found within the recent 3 months.

 

Lawsuit

 

Up to date of reporting, no existing or latent litigation of the subject has been found.

 

 

Special Note

 

Interview Details

Interview Date

2015-9-9

Name

Ms. Zheng

Department

Sales Department

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.66.61

UK Pound

1

Rs.102.30

Euro

1

Rs.74.61

 

 

INFORMATION DETAILS

 

Analysis Done by :

RAS

 

 

Report Prepared by :

ANK

 


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.